Routine Clinical Practice for Patients with Recurrent Ovarian Carcinoma: Results from the TROCADERO Study

International Journal of Gynecological Cancer

Volumn 26, Issue 2, 2016, Pages 240-247

  Freyer, Gilles ^a   Ray Coquard, Isabelle ^b   Fischer, Dorothea ^c   Martín, Antonio González ^d   Kielhorn, Adrian ^e   Chia, Victoria ^e   Nanayakkara, Nuwan ^f   Taylor, Aliki ^g  

^a Institut de Cancérologie des HCL   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d MD ANDERSON CANCER CENTER   (Spain)

^e AMGEN INC   (United States)

^f IQVIA   (United States)

^g AMGEN LTD   (United Kingdom)

Author keywords

Outcomes research; Ovarian cancer; Platinum compounds; Recurrence; Taxane

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PRACTICE; DEMOGRAPHY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; LAPAROTOMY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; CARCINOMA; DRUG RESISTANCE; HOSPITALIZATION; MIDDLE AGED; OVARIAN NEOPLASMS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; HOSPITALIZATION; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957605564     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000590     Document Type: Article

References (14)

1. World Cancer Research Fund and the American Institute for Cancer Research. Continuous Update Report Project Ovarian Cancer 2014 Report: Food, Nutrition, Physical Activity, and the Prevention of Ovarian Cancer 2014. Available at: http://www.aicr.org/continuous-update-project/reports/ovarian-cancer-2014-report.pdf. Accessed Nov. 5, 2015.
2. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. Available at: www.globocan.iarc.fr. Accessed June 12, 2014.
3. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer v.2.2014. Fort Washington, PA: National Comprehensive Cancer Network; 2014.
4. Vasey PA, Herrstedt J, Jelic S, ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma. Ann Oncol. 2005; 16: i13-i15.
5. du Bois A, Quinn M, Thigpen T, 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005; 16: viii7-viii12.
6. Colombo N,. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient. Future Oncol. 2013; 9: 19-23.
7. Fung-Kee-Fung M, Oliver T, Elit L, Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007; 14: 195-208.
8. Friedlander M, Trimble E, Tinker A, Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011; 21: 771-775.
9. González Martín A, Redondo A, Jurado M, GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol. 2013; 15: 509-525.
10. Monk BJ, Herzog TJ, Kaye SB, Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010; 28: 3107-3114.
11. Poveda A, Vergote I, Tjulandin S, Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011; 22: 39-48.
12. Raja FA, Perren TJ, Embleton A, Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Int J Gynecol Cancer. 2013; 23: 47.
13. Aghajanian C, Blank SV, Goff BA, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012; 30: 2039-2045.
14. Ledermann JA, Raja FA, Fotopoulou C, Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24: vi24-vi32.